Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology Learning Network
The GCIG INTERLACE study has demonstrated a significant improvement in 5-year survival rates in advanced cervical cancer, from 72% to 80%, with the addition of induction chemotherapy to standard-of-care chemoradiation.
Oncology, Medical November 13th 2023
The New England Journal of Medicine
The study underscores the potential of osimertinib-chemotherapy combination as a first-line treatment in EGFR-mutated advanced NSCLC, demonstrating a significant improvement in progression-free survival and response rate compared to osimertinib monotherapy.
The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.
Oncology, Medical November 6th 2023
The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.
MDLinx
The discovery that chemotherapy-induced cognitive impairment, or “chemobrain,” may be linked to an excess of calcium inside cells opens new avenues for potential therapies. This breakthrough could lead to treatments that restore cognition in patients experiencing these symptoms.
Neurology November 1st 2023
OBR Oncology
This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.
Oncology, Medical October 23rd 2023